跳至主要内容
临床试验/NCT01630863
NCT01630863Unknown不适用

The Safe Effective Light Dose of Photodynamic Therapy for Chronic Central Serous Chorioretinopathy

Yeungnam University College of Medicine1 个研究点 分布在 1 个国家目标入组 45 人开始时间: 2012年6月最近更新:
适应症

试验速览

阶段
不适用
入组人数
45
试验地点
1
主要终点
Changes of best corrected visual acuity

研究概览

简要总结

To find the safe effective lowest light dose for photodynamic therapy (PDT). in the treatment of central serous chorioretinopathy.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
None

入排标准

年龄范围
20 Years 至 70 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Idiopathic detachment of the neurosensory retina with a focal leak at the level of the RPE with FA
  • Presence of SRF and/or serous pigment epithelial detachment on optical coherence tomography (OCT)
  • Presence of abnormal dilated choroidal vasculature in ICGA
  • Patients with symptomatic CSC of at least 3 months duration

排除标准

  • Patients who received any previous treatment, including PDT or focal thermal laser photocoagulation for CSC, or who had evidence of CNV, PCV, or other maculopathy on clinical examination, FA, or ICGA
  • Patients receiving exogenous corticosteroid treatment
  • Patients with systemic diseases such as Cushing's disease or renal diseases
  • Pregnant patients

结局指标

主要结局

Changes of best corrected visual acuity

时间窗: 6 month

Changes of best corrected visual acuity at baseline and 1, 3, 6 month after PDT

次要结局

  • Change of central retinal thickness, success rate, recurrence rate, and complications(6 months)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Min Sagong

Assistant Professor

Yeungnam University College of Medicine

研究点 (1)

Loading locations...

相似试验